Skip to Main Content

Paper Details

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.
J Immunother Cancer
40
2019
Author NameAffiliation
Ludmila DanilovaBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
Ludmila DanilovaJohns Hopkins University
Ludmila DanilovaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Ludmila DanilovaBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
Ludmila DanilovaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Ludmila DanilovaJohns Hopkins University
Leslie CopeBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
Leslie CopeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Leslie CopeJohns Hopkins University
Victor E VelculescuBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
Victor E VelculescuSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Bert VogelsteinBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
Bert VogelsteinLudwig Center and Howard Hughes Medical Institute, Johns Hopkins University
Kenneth W KinzlerBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
Kenneth W KinzlerLudwig Center and Howard Hughes Medical Institute, Johns Hopkins University
Nickolas PapadopoulosBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
Nickolas PapadopoulosLudwig Center and Howard Hughes Medical Institute, Johns Hopkins University
  • 1 - 17

Datasets